An observational study in Pediatric Renal Failure, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by University Hospital, Strasbourg, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 145 studies in Kidney Failure, Chronic with a site in France — 28 open to participants now, 33 under way, 6 of them phase 3. Kidney Failure, Chronic · France.
Among the 145 studies in Kidney Failure, Chronic with a site in France, this one is the 27th largest by planned enrollment of the 40 observational ones that give a count, is one of 4 that started in 2025, is one of 40 observational ones, reaches primary completion later than 8 of the 32 other live ones, and was the 143rd registered.
2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.
Browse Kidney Failure, Chronic studies →28 of the 145 studies in Kidney Failure, Chronic with a site in France are open now. Recruiting first, the newest first:
Central Hospital, Nancy, France · Sites in France
Ages 18+ · Healthy volunteers
University of Avignon · Sites in France
Ages 20–79
Centre Hospitalier Régional d'Orléans · Sites in France
Ages 18+ · Healthy volunteers
Hospices Civils de Lyon · Sites in France
Ages 6–17 · Men only
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
145 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 16 · Phase 3 26 · Phase 4 9
First in 1994; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 120 across 445 observational studies indexed under Kidney Failure, Chronic.
Median enrollment 70 across the 105 interventional studies, 177 across the 40 observational. Of the 90 that completed or were terminated, 15 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 145 have an industry lead sponsor. The 10 most frequent:
University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.
University Hospital, Strasbourg, France has 4 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
7 of the studies in Kidney Failure, Chronic with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06692231Centre Hospitalier de VichyImpact of Hospital Pharmacist Intervention on Medication Management in Dialysis Patients | 2026-11-30 |
| NCT06474169Centre Hospitalier Régional d'OrléansAssessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic ESKD Patients. | 2026-12 |
| NCT06595680Hospices Civils de LyonDevelopment of an Innovative Hemodialysis Method to Improve Dialytic Clearance of Protein-bound Uremic Toxins | 2027-01-22 |
| NCT06887075University Hospital, BordeauxSystemic Activation of Inflammasomes and Frailty in Older Candidates to Kidney Transplantation | 2027-02-15 |
| NCT05753930Hansa Biopharma ABImlifidase Prior to Kidney Transplant in Highly Sensitised Children | 2027-02-28 |
Add all 7 to your calendar (.ics) → With an account.
Among the 145 studies in Kidney Failure, Chronic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Intraperitoneal pressure (IPP) is an objective measurement used to assess tolerance to fluid volume. IPP has been shown to be strongly correlated with intraperitoneal dialysate volume as well as anthropometric parameters. In observational studies conducted in adults, an IPP greater than 13-14 cmH2O was associated with an increased risk of peritonitis, initiation of hemodialysis, or death.
Measuring IPP is therefore a tool to optimize dialysis prescriptions. However, this measurement is not well standardized, and there is limited scientific evidence regarding its impact on patient management.
Measuring IPP is a tool to optimize dialysis prescriptions. However, this measurement is not well standardized, and there is limited scientific evidence regarding its impact on patient management. Some centers do not perform any measurements, others perform them monthly, and some only during peritoneal equilibration tests.
The hypothesis of this research is to highlight current practices and experiences in measuring intraperitoneal pressures in children undergoing peritoneal dialysis in different European dialysis centers, in order to improve practices regarding PIP prescription.
Healthcare professional working in a European dialysis center
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Healthcare professional working in a European dialysis center
Exclusion Criteria:
- Refusal to participate in the study.
Review of current practices in measuring intraperitoneal pressures in children undergoing peritoneal dialysis
This study aims to provide an overview of current experiences in measuring intraperitoneal pressures in children undergoing peritoneal dialysis in different European dialysis centers.
Time frame: Up to 12 months
Started Jul 2025 (actual). Primary completion is estimated for Jul 2026, 12 months after the start.
Of 132 non-industry observational studies under Kidney Failure, Chronic, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 62. This study's planned 12 months is below that.
Counting every sponsor, half of 151 studies reached it within 29 months; a quarter within 11 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France →